Ventiv Scientific's V-PULSE System Completes First Human Thrombectomy Cases

What Happened

Ventiv Scientific has successfully completed initial human clinical cases for its V-PULSE™ Mechanical Thrombectomy System. This new platform is engineered to remove blood clots from the body's peripheral blood vessels.

Unlike conventional systems that rely on continuous vacuum, the V-PULSE system provides physicians with real-time control over aspiration force at the catheter tip. This design aims to minimize catheter clogging and reduce procedural blood loss during clot removal.

Early clinical experience demonstrated effective clot removal and efficient operation. A physician involved noted the system's ability to capture significant clot burden and offer immediate visual confirmation of thrombus capture.

The company developed V-PULSE to enhance clot extraction performance and improve procedural control for doctors treating thrombotic disease.

The Core Points

Ventiv Scientific completed its first human clinical trials for the V-PULSE™ Mechanical Thrombectomy System.
The system is designed for removing blood clots from the peripheral vasculature.
It features real-time control over aspiration force at the catheter tip, aiming to reduce clogging and blood loss.
Initial clinical experience demonstrated effective clot removal and procedural efficiency.
The technology seeks to improve clot extraction performance and enhance physician control during procedures.
V-PULSE is compatible with aspiration pumps already used in hospitals.

Context in 60 Seconds

Mechanical thrombectomy remains a critical treatment for patients suffering from various thrombotic and embolic vascular diseases, such as Deep Vein Thrombosis (DVT) and Acute Limb Ischemia (ALI). These procedures are essential for restoring blood flow, alleviating symptoms, preserving limbs, and ultimately saving lives.

The ongoing advancement of medical devices in this field aims to refine current treatment options, making them more effective and safer for patients. Systems like V-PULSE contribute to this trend by focusing on improved procedural control and efficiency, which can lead to better outcomes for individuals facing serious vascular complications.

Bottom Line

The successful initial human trials of the V-PULSE system suggest a promising advancement in mechanical thrombectomy, potentially offering physicians more precise control and efficiency in removing blood clots. This could lead to improved treatment options for patients with thrombotic diseases.

Loading briefing details...

Ventiv Scientific's V-PULSE System Completes First Human Thrombectomy Cases

What Happened

The company developed V-PULSE to enhance clot extraction performance and improve procedural control for doctors treating thrombotic disease.

The Core Points

Ventiv Scientific completed its first human clinical trials for the V-PULSE™ Mechanical Thrombectomy System.
The system is designed for removing blood clots from the peripheral vasculature.
It features real-time control over aspiration force at the catheter tip, aiming to reduce clogging and blood loss.
Initial clinical experience demonstrated effective clot removal and procedural efficiency.
The technology seeks to improve clot extraction performance and enhance physician control during procedures.
V-PULSE is compatible with aspiration pumps already used in hospitals.